My clinical pharmacy research interests include: anemia and bone disease management in the chronic kidney disease (CKD) population, specifically investigating newer agents being utilized to treat these disease states and protocol driven practices. Another area of my pharmacy practice research in nephrology is vascular access. Areas of research include access related infections, specifically understanding infection rates, organisms involved and locking devices for catheters and their clinical outcomes. Furthermore, dialysis modalities have evolved and the pharmacokinetics of drugs has also changed. Therefore much of my research has focused on drug clearance with these newer modalities. Lastly, another area of my research is pharmacy practice research. Here we have investigated different pharmacy services for the dialysis patient and outcomes. I have been the lead investigator on a number of research projects in these areas. Please refer to list of publications for the scope of my clinical research.
Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy.
Am J Kidney Dis. 2017 Apr 14;:
PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma (UPS): a clue for intimal sarcoma metastases.
J Cutan Pathol. 2017 Jan 20;:
Oncogene. 2017 Jan 16;:
Excretory/secretory products in the Echinococcus granulosus metacestode: is the intermediate host complacent with infection caused by the larval form of the parasite?
Int J Parasitol. 2016 Oct 19;:
Am J Pharm Educ. 2016 Sep 25;80(7):114
CANNT J. 2016 Jan-Mar;26(1):17-21; quiz 22-3
KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large cell lymphoma.
Br J Dermatol. 2016 Apr 1;
CANNT J. 2015 Oct-Dec;25(4):19-23; quiz 24-5
CANNT J. 2015 Apr-Jun;25(2):40-3; quiz 44-5
CANNT J. 2015 Jan-Mar;25(1):21-3; quiz 24-5